NewAmsterdam Pharma Company N.V (NAMS) Assets & Liabilities 2023-2026
Total assets, cash, long-term debt, book value, and leverage ratios
Assets & Liabilities
Assets, cash, debt, book value, and leverage
- Total Assets
- $732.64M
- Cash
- $457.61M
- Long-Term Debt
- N/A
- Book Value
- $665.22M
- D/E Ratio
- N/A
- Debt/EBITDA
- N/A
Total Assets
Expanding asset base can indicate business growth
Cash & Equivalents
Shows liquidity available for opportunities or downturns
Long-Term Debt
Declining debt trend is generally positive
Book Value (Equity)
Growing book value signals intrinsic value creation
Debt / Equity
Lower means less reliance on borrowed money
Debt / EBITDA
Below 2x is conservative; above 4x is high